Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 9

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
The purpose of this study was to evaluate the effects of ketoprofen (KTP), flunixin meglumine (FLM), and meloxicam (MLX) administration on acute-phase proteins after dehorning in Holstein heifers. A total of 21 Holstein heifers were enrolled into three groups of equal size (n=7) and administered ketoprofen, flunixin meglumine, or meloxicam, at doses of 2.2 mg/kg, 1.1 mg/kg, and 1 mg/kg body weight, respectively. Serum amyloid A, haptoglobin, and ceruloplasmin levels were determined before the administration of the three drugs (0 hrs) and at 6, 12, 24, 48, and 96 hours post-administration. The mean values (±SD) obtained revealed no significant alteration in APP levels at 0 hrs in any of the three groups. Time-dependent alterations, however, were significant in all groups. Group-time interactions were significant (P < 0.001) for ceruloplasmin concentrations, whereas results for serum amyloid A and haptoglobin levels were deemed non-significant. Inter-group interaction revealed no significant findings regarding serum amyloid A and ceruloplasmin levels, but haptoglobin levels showed a significant difference between the KTP and FLM groups at 48 hrs. It may therefore be reasonably suggested that KTP, FLM, and MLX could all be administered to effect slight changes in acute phase proteins.
Canine visceral leishmaniasis is associated with cardiac changes. This study was designed to test the hypothesis that vitamin D and coagulation parameters, such as D-dimer, activated partial thromboplastin time (APTT), partial thromboplastin time (PT), mean platelet volume (MPV), and white blood cell (WBC) levels, change in different stages of canine visceral leishmaniasis (CVL). Thirty-two dogs diagnosed with CVL were classified into four different groups: stage I (mild disease), stage II (moderate disease), stage III (severe disease), stage IV (very severe disease), and healthy controls. The groups were based on clinical signs, rapid ELISA/IFAT, hematological and serum biochemical tests, and urinary protein/creatinine ratios. Serum vitamin D levels were positively correlated with MPV (r = 0.503), but negatively correlated with D-dimer (r =-0.326), APTT (r =-0.361), PT (r =-0.289), and WBC (r = -0.384). The dogs with leishmaniasis showed increased WBC levels compared with the control group. Similarly, their vitamin D levels were significantly decreased compared with those in the control group (p<0.05). Severely diseased dogs (stage IV leishmaniasis) showed the lowest vitamin D levels, but there were no significant differences between dogs in the various stages of leishmaniasis. The evidence provided by this study indicates that the CVL dogs had low-grade systemic coagulation and fibrinolytic activation, as indicated by elevated MPV, PT, WBC and D-dimer levels, which may be used as a biomarker of low-grade systemic inflammation in CVL.
The aim of the present study was to evaluate the efficacy of chloroquine on lessening or eliminating cyst shedding in dogs naturally infected with Giardia duodenalis. A total of 26 dogs naturally infected with G. duodenalis, from various breeds, ages and of both sexes were selected and randomly assigned into two groups based on treatment (group I, n = 20 dogs treated orally with 2.5 mg/kg chloroquine twice daily for 5 consecutive days) and control (group II, n = 6 untreated control dogs). Diagnosis was based on microscopic faecal examination and rapid test kits. Cyst excretion was determined on days 0, 3, 7 and 10, before and after treatment. Evaluation of the percentage reduction in cyst excretion revealed 99.8% efficacy on day 3 and 99.9% on days 7 and 10 in the treatment group. Geometric means of the number of excreted cysts did not change significantly in the control group. Chloroquine at the proposed dosage might be a practical in application, low priced and highly effective treatment option in dogs with giardiasis.
Vector-borne diseases in dogs are a major health problem of zoonotic importance. Canine monocytic ehrlichiosis (CME) is one of the most common vector-borne infections in dogs. Co-infections with vectorborne diseases are reported to cause more severe pathological effects than mono-infections. The current study investigates the effects of mono- and co-infections with CME on oxidative status and lipid profiles in dogs. Dogs with vector-borne diseases were divided into two groups, mono-infected (n = 22) and co-infected (n = 23) with CME, and compared to a healthy group (n = 20). Double and triple co-infections with other vector-borne diseases included A. phagocytophilum, L. infantum, and D. immitis. The serum lipid profile (high-density lipoprotein (HDL), low-density lipoprotein (LDL), cholesterol, and triglycerides) and the total and individual markers of oxidative status (total antioxidant capacity (TAC), total oxidant status (TOS), malondialdehyde (MDA), paraoxonase (PON-1), and arylesterase (ARE)) were evaluated. Significant decreases in PON-1 and ARE enzyme activities and HDL concentration, as well as increases in TOS level, MDA, LDL, and triglyceride concentrations were determined in both mono- and co-infected groups compared to the healthy control group. No significant differences between the groups were found in the TAC level or cholesterol concentration. In conclusion, alterations in lipid profile and increase in oxidative stress were observed in dogs with CME compared to the healthy control group, however, no significant differences were detected between mono- and co-infected dogs.
The purpose of this prospective, double-blinded, and placebo-controlled clinical trial was to investigate the efficacy of topical cream, containing 0.1% retinoic acid for the treatment of tail gland hyperplasia in cats. Nineteen privately owned cats diagnosed with tail gland hyperplasia, based on history and clinical findings were randomly assigned to either a placebo or an active ingredient treatment group. Clinical evaluations were done by the same investigator, who scored clinical healing, at the beginning, during, and at the end of the treatment. Both owners and investigators were blinded to the allocation to the groups. It was demonstrated that retinoic acid gel treatment significantly decreased (P<0.05) the investigator's clinical scores while no significant changes were detected in the placebo treatment group. In conclusion, treatment with 0.1% retinoic acid cream was effective for the topical management of tail gland hyperplasia in the cats included in the study.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.